Skip to main content
SpringerLink
Log in

Familial Endocrine Conditions

  • Chapter
  • First Online:
Endocrine Surgery

Part of the book series: Springer Specialist Surgery Series ((SPECIALIST))

Endocrine diseases most commonly occur in a sporadic manner but may have a hereditary background and be part of a complex syndrome. A variety of familial endocrine conditions exist such as the Carney complex [1], the Cowden syndrome [2], the von Hippel-Lindau syndrome [3], the hyperparathyroidism-jaw tumor syndrome [4], and the pheochromocytoma–paraganglioma syndrome [5] (Table 43.1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Stratakis CA. Adrenocortical tumors, primary pigmented adrenocortical disease (PPNAD)/Carney complex, and other bilateral hyperplasias: the NIH studies. Horm Metab Res. 2007;39(6):467–73.

    Article  PubMed  CAS  Google Scholar 

  2. Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet. 2004;41(5):323–6.

    Article  PubMed  CAS  Google Scholar 

  3. Shuin T, Yamasaki I, Tamura K, Okuda H, Furihata M, Ashida S. Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment. Jpn J Clin Oncol. 2006;36(6):337–43.

    Article  PubMed  Google Scholar 

  4. Jackson CE, Norum RA, Boyd SB, et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery. 1990;108(6):1006–12; discussion 12–3.

    PubMed  CAS  Google Scholar 

  5. Schiavi F, Savvoukidis T, Trabalzini F, et al. Paraganglioma syndrome: SDHB, SDHC, and SDHD mutations in head and neck paragangliomas. Ann N Y Acad Sci. 2006;1073:190–7.

    Article  PubMed  Google Scholar 

  6. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med. 1954;16(3):363–71.

    Article  PubMed  CAS  Google Scholar 

  7. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276(5311):404–7.

    Article  PubMed  CAS  Google Scholar 

  8. Teh BT, Esapa CT, Houlston R, et al. A family with isolated hyperparathyroidism segregating a missense MEN1 mutation and showing loss of the wild-type alleles in the parathyroid tumors. Am J Hum Genet. 1998;63(5):1544–9.

    Article  PubMed  CAS  Google Scholar 

  9. Kassem M, Kruse TA, Wong FK, Larsson C, Teh BT. Familial isolated hyperparathyroidism as a variant of multiple endocrine neoplasia type 1 in a large Danish pedigree. J Clin Endocrinol Metab. 2000;85(1):165–7.

    Article  PubMed  CAS  Google Scholar 

  10. Schaaf L, Pickel J, Zinner K, et al. Developing effective screening strategies in multiple endocrine neoplasia type 1 (MEN 1) on the basis of clinical and sequencing data of German patients with MEN 1. Exp Clin Endocrinol Diabetes. 2007;115(8):509–17.

    Article  PubMed  CAS  Google Scholar 

  11. Oberg K, Skogseid B. The ultimate biochemical diagnosis of endocrine pancreatic tumours in MEN-1. J Intern Med. 1998;243(6):471–6.

    Article  PubMed  CAS  Google Scholar 

  12. Karges W, Schaaf L, Dralle H, Boehm BO. Concepts for screening and diagnostic follow-up in multiple endocrine neoplasia type 1 (MEN1). Exp Clin Endocrinol Diabetes. 2000;108(5):334–40.

    Article  PubMed  CAS  Google Scholar 

  13. Brandi ML, Gagel RF, Angeli A, et al. Consensus: guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–71.

    Article  PubMed  CAS  Google Scholar 

  14. Thomas-Marques L, Murat A, Delemer B, et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol. 2006;101(2):266–73.

    Article  PubMed  Google Scholar 

  15. Triponez F, Dosseh D, Goudet P, et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg. 2006;243(2):265–72.

    Article  PubMed  Google Scholar 

  16. Anlauf M, Garbrecht N, Henopp T, et al. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinicopathological and epidemiological features. World J Gastroenterol. 2006;12(34):5440–6.

    PubMed  Google Scholar 

  17. Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma – incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66(7):711–9.

    PubMed  CAS  Google Scholar 

  18. Skogseid B, Rastad J, Gobl A, et al. Adrenal lesion in multiple endocrine neoplasia type 1. Surgery. 1995;118(6):1077–82.

    Article  PubMed  CAS  Google Scholar 

  19. Barzon L, Pasquali C, Grigoletto C, Pedrazzoli S, Boscaro M, Fallo F. Multiple endocrine neoplasia type 1 and adrenal lesions. J Urol. 2001;166(1):24–7.

    Article  PubMed  CAS  Google Scholar 

  20. Dackiw AP, Cote GJ, Fleming JB, et al. Screening for MEN1 mutations in patients with atypical endocrine neoplasia. Surgery. 1999;126(6):1097–103; discussion 103–4.

    Article  PubMed  CAS  Google Scholar 

  21. Teh BT, Zedenius J, Kytola S, et al. Thymic carcinoids in multiple endocrine neoplasia type 1. Ann Surg. 1998;228(1):99–105.

    Article  PubMed  CAS  Google Scholar 

  22. Lim LC, Tan MH, Eng C, Teh BT, Rajasoorya RC. Thymic carcinoid in multiple endocrine neoplasia 1: genotype-phenotype correlation and prevention. J Intern Med. 2006;259(4):428–32.

    Article  PubMed  CAS  Google Scholar 

  23. Soga J, Yakuwa Y, Osaka M. Evaluation of 342 cases of mediastinal/thymic carcinoids collected from literature: a comparative study between typical carcinoids and atypical varieties. Ann Thorac Cardiovasc Surg. 1999;5(5):285–92.

    PubMed  CAS  Google Scholar 

  24. Gauger PG, Scheiman JM, Wamsteker EJ, Richards ML, Doherty GM, Thompson NW. Role of endoscopic ultrasonography in screening and treatment of pancreatic endocrine tumours in asymptomatic patients with multiple endocrine neoplasia type 1. Br J Surg. 2003;90(6):748–54.

    Article  PubMed  CAS  Google Scholar 

  25. Langer P, Kann PH, Fendrich V, et al. Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. World J Surg. 2004;28(12):1317–22.

    Article  PubMed  Google Scholar 

  26. Imamura M, Takahashi K, Adachi H, et al. Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome. Ann Surg. 1987;205(3):230–9.

    Article  PubMed  CAS  Google Scholar 

  27. Hayasaka K, Nihashi T, Matsuura T, Itoh K, Tokuda H. Usefulness of F-18 FDG-PET in detection of multiple endocrine tumors with duodenal carcinoid. Comput Med Imaging Graph. 2007;31(3):191–4.

    Article  PubMed  Google Scholar 

  28. Whipple AO, Frantz VK. Adenoma of islet cells with hyperinsulinism: a review. Ann Surg. 1935;101(6):1299–335.

    Article  PubMed  CAS  Google Scholar 

  29. Doppman JL, Miller DL, Chang R, Shawker TH, Gorden P, Norton JA. Insulinomas: localization with selective intraarterial injection of calcium. Radiology. 1991;178(1):237–41.

    PubMed  CAS  Google Scholar 

  30. Gimm O, Konig E, Thanh PN, Brauckhoff M, Karges W, Dralle H. Intra-operative quick insulin assay to confirm complete resection of insulinomas guided by selective arterial calcium injection (SACI). Langenbecks Arch Surg. 2007;392(6):679–84.

    Google Scholar 

  31. de Herder WW, Kwekkeboom DJ, Valkema R, et al. Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest. 2005;28(11 Suppl International):132–6.

    PubMed  Google Scholar 

  32. Bertherat J, Tenenbaum F, Perlemoine K, et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab. 2003;88(11):5353–60.

    Article  PubMed  CAS  Google Scholar 

  33. Arnalsteen LC, Alesina PF, Quiereux JL, et al. Long-term results of less than total parathyroidectomy for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery. 2002;132(6):4–24; discussion 24–5.

    Article  Google Scholar 

  34. Doherty GM, Lairmore TC, DeBenedetti MK. Multiple endocrine neoplasia type 1 parathyroid adenoma development over time. World J Surg. 2004;28(11):1139–42.

    Article  PubMed  Google Scholar 

  35. Hellman P, Skogseid B, Oberg K, Juhlin C, Akerstrom G, Rastad J. Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1. Surgery. 1998;124(6):993–9.

    Article  PubMed  CAS  Google Scholar 

  36. Dionisi S, Minisola S, Pepe J, et al. Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type 1: presentation as hypercalcemic crisis. Mayo Clin Proc. 2002;77(8):866–9.

    Article  PubMed  Google Scholar 

  37. Burgess JR, David R, Parameswaran V, Greenaway TM, Shepherd JJ. The outcome of subtotal parathyroidectomy for the treatment of hyperparathyroidism in multiple endocrine neoplasia type 1. Arch Surg. 1998;133(2):126–9.

    Article  PubMed  CAS  Google Scholar 

  38. Bartsch DK, Langer P, Wild A, et al. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance? Surgery. 2000;128(6):958–66.

    Article  PubMed  CAS  Google Scholar 

  39. Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg. 2005;242(6):757–64, discussion 64–6.

    Article  PubMed  Google Scholar 

  40. Tonelli F, Fratini G, Nesi G, et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg. 2006;244(1):61–70.

    Article  PubMed  Google Scholar 

  41. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg. 2001;234(4):495–505; discussion 6.

    Article  PubMed  CAS  Google Scholar 

  42. Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med. 1998;243(6):495–500.

    Article  PubMed  CAS  Google Scholar 

  43. Carneiro DM, Levi JU, Irvin GL, 3rd. Rapid insulin assay for intraoperative confirmation of complete resection of insulinomas. Surgery. 2002;132(6):937–43.

    Google Scholar 

  44. Richards ML, Gauger P, Thompson NW, Giordano TJ. Regression of type II gastric carcinoids in multiple endocrine neoplasia type 1 patients with Zollinger-Ellison syndrome after surgical excision of all gastrinomas. World J Surg. 2004;28(7):652–8.

    Article  PubMed  Google Scholar 

  45. Burgess JR, Giles N, Shepherd JJ. Malignant thymic carcinoid is not prevented by transcervical thymectomy in multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf). 2001;55(5):689–93.

    Article  CAS  Google Scholar 

  46. Machens A, Schaaf L, Karges W, et al. Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf). 2007;67(4):613–22.

    Google Scholar 

  47. O'Doherty MJ, Kettle AG, Wells P, Collins RE, Coakley AJ. Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies. J Nucl Med. 1992;33(3):313–8.

    PubMed  Google Scholar 

  48. Hellman P, Ahlstrom H, Bergstrom M, et al. Positron emission tomography with 11C-methionine in hyperparathyroidism. Surgery. 1994;116(6):974–81.

    PubMed  CAS  Google Scholar 

  49. Casanova D, Sarfati E, De Francisco A, Amado JA, Arias M, Dubost C. Secondary hyperparathyroidism: diagnosis of site of recurrence. World J Surg. 1991;15(4):546–9; discussion 9–50.

    Article  PubMed  CAS  Google Scholar 

  50. O'Riordain DS, O'Brien T, Grant CS, Weaver A, Gharib H, van Heerden JA. Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2. Surgery. 1993;114(6):1031–7; discussion 7–9.

    PubMed  Google Scholar 

  51. Mulligan LM, Kwok JBJ, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458–60.

    Article  PubMed  CAS  Google Scholar 

  52. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium. JAMA. 1996;276:1575–9.

    Article  PubMed  CAS  Google Scholar 

  53. Carlson KM, Dou S, Chi D, et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A. 1994;91(4):1579–83.

    Article  PubMed  CAS  Google Scholar 

  54. Gimm O, Marsh DJ, Andrew SD, et al. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab. 1997;82(11):3902–4.

    Article  PubMed  CAS  Google Scholar 

  55. Lesueur F, Cebrian A, Robledo M, et al. Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A. Cancer Res. 2006;66(2):1177–80.

    Article  PubMed  CAS  Google Scholar 

  56. Robinson MF, Gagel RF, Raue F. Screening for MEN 2 with biochemical and genetic markers. Recent Results Cancer Res. 1992;125:105–23.

    PubMed  CAS  Google Scholar 

  57. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346(19):1459–66.

    Article  PubMed  CAS  Google Scholar 

  58. Ponder BA, Ponder MA, Coffey R, et al. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1988;1(8582):397–401.

    Article  PubMed  CAS  Google Scholar 

  59. Casanova S, Rosenberg-Bourgin M, Farkas D, et al. Phaeochromocytoma in multiple endocrine neoplasia type 2 A: survey of 100 cases. Clin Endocrinol (Oxf). 1993;38(5):531–7.

    Article  CAS  Google Scholar 

  60. Modigliani E, Vasen HM, Raue K, et al. Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group. J Intern Med. 1995;238(4):363–7.

    Article  PubMed  CAS  Google Scholar 

  61. Sipple JH. The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med. 1961;31:163–6.

    Article  Google Scholar 

  62. Gorlin RJ, Vickers RA. Multiple mucosal neuromas, pheochromocytoma, medullary carcinoma of the thyroid and marfanoid body build with muscle wasting: reexamination of a syndrome of neural crest malmigration. Birth Defects Orig Artic Ser. 1971;7(6):69–72.

    PubMed  CAS  Google Scholar 

  63. Pujol RM, Matias-Guiu X, Miralles J, Colomer A, de Moragas JM. Multiple idiopathic mucosal neuromas: a minor form of multiple endocrine neoplasia type 2B or a new entity? J Am Acad Dermatol. 1997;37(2 Pt 2):349–52.

    Article  PubMed  CAS  Google Scholar 

  64. Gordon CM, Majzoub JA, Marsh DJ, et al. Four cases of mucosal neuroma syndrome: multiple endocrine neoplasm 2B or not 2B? J Clin Endocrinol Metab. 1998;83(1):17–20.

    Article  PubMed  CAS  Google Scholar 

  65. Gomez JM, Biarnes J, Volpini V, Marti T. Neuromas and prominent corneal nerves without MEN 2B. Ann Endocrinol (Paris). 1998;59(6):492–4.

    CAS  Google Scholar 

  66. Wells SA, Jr, Baylin SB, Linehan WM, Farrell RE, Cox EB, Cooper CW. Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann Surg. 1978;188(2):139–41.

    Article  PubMed  Google Scholar 

  67. Lips CJM, Landsvater RM, Hoppener JWM, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med. 1994;331:828–35.

    Article  PubMed  CAS  Google Scholar 

  68. Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med. 1999;340(24):1872–9.

    Article  PubMed  CAS  Google Scholar 

  69. Brink I, Hoegerle S, Klisch J, Bley TA. Imaging of pheochromocytoma and paraganglioma. Fam Cancer. 2005;4(1):61–8.

    Article  PubMed  CAS  Google Scholar 

  70. Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg. 2007;32(10):1960–5.

    Google Scholar 

  71. Leboulleux S, Travagli JP, Caillou B, et al. Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course. Cancer. 2002;94(1):44–50.

    Article  PubMed  CAS  Google Scholar 

  72. de Groot JW, Plukker JT, Wolffenbuttel BH, Wiggers T, Sluiter WJ, Links TP. Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol (Oxf). 2006;65(6):729–36.

    Article  Google Scholar 

  73. Machens A, Hofmann C, Hauptmann S, Dralle H. Locoregional recurrence and death from medullary thyroid carcinoma in a contemporaneous series: 5-year results. Eur J Endocrinol. 2007;157(1):85–93.

    Article  PubMed  CAS  Google Scholar 

  74. Czepczynski R, Parisella MG, Kosowicz J, et al. Somatostatin receptor scintigraphy using (99m)Tc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007;34(10):1635–45.

    Article  PubMed  CAS  Google Scholar 

  75. Iagaru A, Masamed R, Singer PA, Conti PS. Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT. Mol Imaging Biol. 2007;9(2):72–7.

    Article  PubMed  Google Scholar 

  76. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90(11):6077–84.

    Article  PubMed  CAS  Google Scholar 

  77. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer. 1984;53(2):278–85.

    Article  PubMed  CAS  Google Scholar 

  78. Takata MC, Kebebew E, Clark OH, Duh QY. Laparoscopic bilateral adrenalectomy: results for 30 consecutive cases. Surg Endosc. 2007;22(1):202–7.

    Google Scholar 

  79. Miyauchi A, Futami H, Hai N, et al. Two germline missense mutations at codons 804 and 806 of the RET proto- oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res. 1999;90(1):1–5.

    PubMed  CAS  Google Scholar 

  80. Kasprzak L, Nolet S, Gaboury L, et al. Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET. J Med Genet. 2001;38(11):784–7.

    Article  PubMed  CAS  Google Scholar 

  81. Menko FH, van der Luijt RB, de Valk IA, et al. Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918. J Clin Endocrinol Metab. 2002;87(1):393–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University Hospital, Linköping, Sweden

    Oliver Gimm (MD)

Authors
  1. Oliver Gimm
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, United Kingdom

    Johnathan Hubbard

  2. Coll Physicians & Surgeons Columbia, Fort Washington Avenue 161, New York, 10032, U.S.A.

    William B. Inabnet

  3. Queen Mary Hospital, University of Hong Kong Medical Centre, Pokfulam, Hong Kong, China, People's Republic

    Chung-Yau Lo

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag London Limited

About this chapter

Cite this chapter

Gimm, O. (2009). Familial Endocrine Conditions. In: Hubbard, J., Inabnet, W., Lo, CY. (eds) Endocrine Surgery. Springer Specialist Surgery Series. Springer, London. https://doi.org/10.1007/978-1-84628-881-4_43

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-881-4_43

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-880-7

  • Online ISBN: 978-1-84628-881-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation